From owner-sci-resources@net.bio.net Mon May 01 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA CA-95-012 - V24(15) 04/28/95 Date: 2 May 1995 09:53:33 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 552 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <3o5o2d$gmg@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA CA95012 CA-95-012 P1O1 *************************************** INVESTIGATOR GRANTS FOR CLINICAL CANCER THERAPY RESEARCH NIH GUIDE, Volume 24, Number 15, April 28, 1995 RFA: CA-95-012 P.T. 34; K.W. 0715035, 0745070 National Cancer Institute Letter of Intent Receipt Date: September 1, 1995 Application Receipt Date: October 20, 1995 PURPOSE The Cancer Therapy Evaluation Program (CTEP) and the Biological Response Modifiers Program (BRMP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI) invites research grant applications for the conduct of therapeutic clinical trials research employing new agents, concepts, or strategies for the treatment of cancer. This initiative is aimed at encouraging new clinical investigators who have not previously had independent grant funding to submit research applications in this area of research. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Investigator Grants for Clinical Cancer Therapy Research, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic non-profit and for-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State or local governments, and eligible agencies of the Federal government. Applications from minority and women investigators are encouraged. An important principle to remember is that the more extensive the prior independent research experiences, regardless of funding sources, the greater likelihood there will be diminished priority for award. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) individual research grant (R01) as its funding mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to the present RFA may not exceed four years. The direct cost for the four year period may not exceed $500,000. The direct cost in any budget period may not exceed $150,000. The anticipated award date is July 1996. Awards and level of support depend on receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is contingent upon the continuing availability of funds for this purpose. This RFA is a one-time solicitation for new applications for award in FY 96. NCI encourages investigators who responded to the previous solicitation (RFA CA-94-014) to resubmit. The NCI has plans to re- issue this RFA for funding in 1997. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. FUNDS AVAILABLE Approximately $2,000,000 in total costs per year for each of four years will be committed to fund applications submitted in response to this RFA. It is anticipated that ten new individual awards will be made. RESEARCH OBJECTIVES Background In the past year, a number of groups have expressed concern over the declining number of clinical investigators entering and remaining in academic research. Clinical investigators are a critical component in translating new therapeutic agents and modalities from the laboratory into the clinic. They must maintain a broad perspective and knowledge concerning clinical and basic sciences, while developing new cancer therapies that are hypothesis driven. They are highly interactive with basic and clinical researchers in related disciplines. This translational clinician is considered distinct >From the clinician who also has a PhD or equivalent training and concentrates on basic research or the clinician who participates in cancer research solely by entering patients on clinical trials. The Clinical Investigations Task Force of the National Cancer Advisory Board and a sub-committee of the American Association of Clinical Oncology (ASCO) have both been addressing the problem of the decreasing number of academic clinical investigators. One of the problems identified is the lack of suitable mechanisms for the training and funding of clinical oriented investigators involved in translating basic research into new cancer treatments. The traditional grants mechanisms (R01, R29) are under-utilized and often do not fit the needs of young clinical investigators for the support of clinical trials research. The R29 grant mechanism requires the investigator to devote at least 50 percent effort to a five year project and the yearly budget is limited to approximately $70,000. Most clinicians have major clinical and teaching responsibilities and it is impossible to support both the clinical and laboratory components needed within the budget limitations of an R29 grant. New clinical investigators often do not have the publication or research track record to be competitive for R01 grant support. Thus, very few clinical trial research applications are submitted by new clinical investigators. DCT would like to reverse this trend and encourage new clinical investigators, who have not previously received R01 or R29 grant support, to submit grant applications for the conduct of translational clinical trials research. Project Description The Cancer Therapy Evaluations Program and the Biological Response Modifiers Program encourage qualified clinical investigators to develop R01 grant applications for the conduct of cancer clinical trials research on new therapeutic agents and modalities. Grant applications must include clinical trials involving human subjects and designed to ultimately improve cancer survival. The clinical trials must have a strong rationale and be based upon preclinical data, preferably generated by the applicant or collaborators, that support the underlying hypotheses. New clinical therapeutic trials employing drugs (including differentiating agents), biologics (including cytokines, antibodies), vaccine strategies, radiation, or surgery whether used as a single agent/modality or in combination are appropriate. Investigators are urged especially to address the more difficult therapeutic challenges, including the most common malignancies (e.g., breast, ovarian, prostrate, lung). Laboratory studies to monitor patients or to study the mechanism of antitumor effect and resistance should be included. The laboratory studies should be in support of the clinical trial, such that their conduct leads to a greater understanding of the relationship of the therapy and biological changes in the patient or the mechanism of action of an anti-tumor response. Laboratory studies would include pharmacokinetic studies of cytotoxic, immune-modulating, differentiation-inducing, and/or targeted therapeutic agents or relevant pharmacodynamic correlative studies. Measurement of particular biological responses would also be desirable particularly when this information would be relevant to the interpretation of the success or failure of the therapy in individual patients on the clinical trial. It is expected that a significant level of effort, at least 25 percent, will be committed to the research project by the Principle Investigator. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator must be included with the application. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results >From the NIH Revitalization Act of 1993 (Section 4928 of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by September 1, 1995, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is be sent to: Ms. Diane Bronzert Division of Cancer Treatment National Cancer Institute Executive Plaza North, Room 734 Bethesda, MD 20892 Telephone: (301) 496-8866 FAX: (301) 480-4663 APPLICATION PROCEDURES The research grant application form PHS 398, (rev. 9/91) is to be used in applying for this RFA. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7248; and from the NCI program staff listed under INQUIRIES. The RFA label available in the PHS 398 application form must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA number and title must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact photocopies, in one package to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive, Room 1040 MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for express/courier service) At the time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Room 636 6130 Executive Boulevard Bethesda, MD 20892 Bethesda, MD 20852 (for express mail) Applications must be received by October 20, 1995. If an application is received after that date, it will be returned. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. B. Special Instructions for the Completion of the PHS 398 Application NIH has recently been designated a "re-invention laboratory" by the Public Health Service. One component of our efforts to streamline NIH operations is to simplify the grant application and review process. Therefore, an experiment is being conducted to determine ways to reduce the administrative burden in applying for an NIH grant without compromising those elements needed by the initial scientific peer review group to assess the scientific merit of the application and the reasonableness of the proposed budget. In responding to the RFA, the following are specific instructions for sections of the PHS 398 application form (rev. 9/91) that should be completed differently from usual. Some sections are modified and others in the application do not need to be completed for the submission of the application but WILL be requested if your application receives a priority score in the fundable range. For all other items in the application, follow the usual instructions on pages 9-32 of the PHS 398 booklet. FACE PAGE (Form AA) - The title and number of the RFA must be typed in line 2a. Failure to do so could result in delayed processing of your application such that it may not reach the review committee in time for review. Item 10, INVENTIONS AND PATENTS - Do not complete. See Specific Instructions - Appendix for Instructions. FORM DD - PAGE 4 - DETAILED BUDGET PAGE FOR INITIAL BUDGET PERIOD Enter direct costs only for the following: o Personnel, Patient Care Costs, Alterations-Renovations - Complete these sections as instructed in the PHS 398 booklet. o Consultant Costs - Itemize only if proposed consultant costs exceed $10,000 or if a consultant is identified as key personnel. o Equipment - Itemize only individual equipment items in excess of $10,000. o Supplies - Itemize (a) all animal costs and (b) any individual supply item which costs more than $10,000. If animals are involved, state their unit purchase and care costs. Enter total animal costs and supply costs on separate lines. o Travel and Other Expenses - Itemize any expense category that exceeds $5,000. Form EE - Page 5 - BUDGET FOR ENTIRE PROPOSED PROJECT PERIOD - Do not complete this page. Unless you are requesting unusual increases or decreases in future years, they will be automatically escalated on the direct costs proposed for the first year (minus one time costs for equipment) by four percent. Form FF - Page 6 - BIOGRAPHICAL SKETCH - For each KEY person only, provide a two-page biographical sketch. Name, Position Title, Education - Complete these sections as instructed in the PHS 398 booklet. Research and Professional Experience - Identify your research background and experience relevant to the research proposed. Specifically, provide: o A list of previous research positions that are felt to be of significance or relevance for the review of the proposed research; o Complete references, titles, and authors on all peer-reviewed publications representative of your research career or pertinent to the research proposed; o The title and funding source of all active research grants or contracts on which you are principal investigator, co-investigator, or project leader. Indicate current percent effort for each award. o The title and length of service on any peer review group, council, or program advisory committee. Form GG - Page 7 - OTHER SUPPORT - Do not complete. Updated information will be requested by NCI staff from only those applicants being considered for funding. Form HH - Page 8 - RESOURCES AND ENVIRONMENT - Complete this section as requested in the PHS 398 form. SPECIFIC INSTRUCTIONS - RESEARCH PLAN (Booklet Pages 19-24) - Applications in response to this RFA should be concise and shorter than regular grant applications. Items 1-4 may not exceed 20 pages in total. Item 1 - Specific Aims - In one page or less, list in priority order, the broad, long-range objectives. Describe concisely and realistically the hypothesis to be tested and what the specific research described in this application is intended to accomplish. Item 2 - Background and Significance - In two to three pages, use this section to describe (a) how the proposed research will contribute to meeting the goals and objectives of the RFA; and, (b) explain the rationale for the selection of the general methods and approaches proposed to accomplish your specific aims. Items 3-4 - Progress Report/Preliminary Studies, Research Design and Methods - In seventeen pages or less, complete as instructed on pages 20-21 of the PHS 398 booklet with the modification that the clinical protocol(s) and up to six publications, manuscripts submitted or accepted for publication, patents, or invention reports can be included in the Appendix (see below). Investigator may use this section to address the following: o preliminary studies pertinent to the application; o rationale and hypothesis for the clinical trial and laboratory studies. o general methods that will be utilized; provide specific details for those techniques which are unique or where a significant departure from a generally accepted technique is important for reviewers to know; o outcome measures that will be used to assess the success or failure of each set of experiments (include statistical analyses for laboratory and clinical studies); o plans for the rigorous data management and verification of research data; o potential pitfalls in the experimental design and alternative studies that will be done if the proposed experiments fail. Items 5-6 - Human Subjects, Vertebrate Animals - Complete as described on pages 22-23. State clearly the plans for early detection of and protection against adverse effects on human subjects. Documentation for the composition of the proposed study population in terms of gender and racial/ethnic group together with a rationale for its choice must be included in the Human Subjects section. Item 7 - Consultants/Collaborators - Biographical sketches should conform to the brief format described previously for Form FF. Item 8 - Consortium, Contractual Arrangements - In one page or less, provide a brief explanation of the programmatic fiscal and administrative arrangements made with collaborating organizations. Item 9 - Literature Cited - In five pages or less, give full literature citations including the title of the article. SPECIFIC INSTRUCTIONS - APPENDIX (Page 24) - Up to ten publications, manuscripts submitted or accepted for publication, patents, and invention reports may be provided. Clinical protocol(s) must be included in this section. Other than this change, complete as instructed. Questions regarding these instructions may be directed to the program staff listed under INQUIRIES. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by the Division of Research Grants (DRG) for completeness and by the NCI for responsiveness. Incomplete applications will be returned to the applicant without further consideration. If the application is not responsive to the RFA, NCI staff may contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next review cycle. Applications that are complete and responsive to the Request for Applications will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NCI in accordance with the review criteria stated below. As part of the initial merit review, all applications will receive a written critique and may undergo a process in which only those applications deemed to have the highest scientific merit will be discussed, assigned a priority score, and receive a second level review by the National Cancer Advisory Board. The review group will assess the scientific merit of the studies using the following review criteria: 1. Importance, timeliness, and clinical merit of the clinical trials. 2. Quality of data supporting the proposed clinical trial. 3. Scientific and technical merit of the proposed laboratory studies. 4. Relevance of the proposed laboratory studies to the clinical trials. 5. Research training and clinical qualifications of the Principal Investigator and staff in the area of the proposed research. 6. Availability and quality of the resources necessary to perform research. 7. Quality of data verification and management plans and statistical analysis. The initial review group will critically examine the submitted budget and will recommend an appropriate budget and period of support for each approved application. They will also examine the provisions for the protection of human and animal subjects, the safety of the research environment, and conformance with the NIH Guidelines for the Inclusion of Women and Minorities as Subjects in Clinical Research. AWARD CRITERIA Applications considered by the National Cancer Advisory Board will be considered for award based upon (a) scientific and technical merit; (b) availability of funds; and (c) programmatic priorities. Preference will also be given to clinical investigators who are new to this research area. Letter of Intent Receipt Date: September 1, 1995 Application Receipt Date: October 20, 1995 Review by National Cancer Advisory Board: May 1996 Anticipated Award Date: July 1996 INQUIRIES Written and telephone inquiries concerning the objectives and scope of this RFA and inquiries about whether or not specific proposed research would be responsive are strongly encouraged. The program staff welcome the opportunity to clarify any issues or questions from potential applicants. Direct inquiries regarding general programmatic issues and chemotherapy agents to: Ms. Diane Bronzert Division of Cancer Treatment National Cancer Institute Executive Plaza North, Room 734 6130 Executive Boulevard MSC 7432 Bethesda, MD 20892-7432 Telephone: (301) 496-8866 FAX: (301) 480-4663 Email: BRONZERD@DCT.NCI.NIH.GOV Direct inquiries regarding programmatic issues using biologics to: Dr. Toby Hecht Division of Cancer Treatment National Cancer Institute FCRDC 1052, Room 247 Bethesda, MD 20892 Telephone: (301) 846-1098 FAX: (301) 846-5429 Email: HECHT@NCIFCRF.GOV Direct inquiries regarding fiscal matters to: Ms. Eileen M. Natoli Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6120 Executive Boulevard MSC 7150 Bethesda, MD 20892-7150 Telephone: (301) 496-7800, ext. 256 FAX: (301) 496-8601 Email: NATOLIE@GAB.NCI.NIH.GOV AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No 93.395, Cancer Treatment Research. Awards are made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended, Public Law 99-158, 42 USC 241 and 285) and administered under HHS grants policies. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routing education, library, day care, health care or early childhood development services are provided to children. This is consistent with the phs mission to protect and advance the physical and mental health of the american people. From owner-sci-resources@net.bio.net Mon May 01 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA MH-95-003 - V24(15) 04/28/95 Date: 2 May 1995 09:53:42 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 433 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <3o5o2m$gn4@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA MH95003 MH-95-003 P1O1 *************************************** ROLE OF THE BLOOD BRAIN BARRIER IN HIV NEUROPATHOGENESIS NIH GUIDE, Volume 24, Number 15, April 28, 1995 RFA: MH-95-003 P.T. 34; K.W. 0715008, 1002030 National Institute of Mental Health National Institute of Neurological Disorders and Stroke Letter of Intent Receipt Date: May 22, 1995 Application Receipt Date: June 27, 1995 PURPOSE The Office on AIDS, National Institute of Mental Health (NIMH), supports investigations directed at developing effective strategies to prevent or reduce behaviors that place individuals at risk for HIV infection and fosters research to enhance the understanding of the profound impact of the Human Immunodeficiency Virus (HIV) infection on the central nervous system (CNS). In addition, the National Institute of Neurological Disorders and Stroke (NINDS) supports research on neurological aspects of HIV infection (neuro-AIDS) in adults and children. The principal objective of this Request for Applications (RFA) is to stimulate research on the role of the blood brain barrier (BBB) in the neuropathogenesis of HIV infection and disease progression. The results of these investigations are expected to constitute preliminary data for proposals to block HIV entry into the CNS, and prevent the detrimental effects of the virus on the CNS. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Role of the Blood Brain Barrier in HIV Neuropathogenesis, is related to the priority areas of HIV infection of the nervous system and mental health and disorders. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone (202) 783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT The mechanisms available for support of this RFA are the National Institutes of Health (NIH) research project grant (R01), FIRST (R29) award, small grant award (R03-NIMH only), and the investigator-initiated interactive research project grant. Responsibility for the planning, direction, and execution of the proposed research project will be solely that of the applicant. The anticipated award date is September 1995. Because the nature and scope of the research proposed in response to this RFA may vary, it is anticipated that the size of an award will also vary. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. FUNDS AVAILABLE In fiscal year 1995, a total of $1.5 million contributed equally by NIMH and NINDS has been set aside for this RFA for about six to ten awards. Support may be requested for a period of up to five years. Foreign applicants may request no more than three years of support. RESEARCH OBJECTIVES Background The CNS appears to be a prime target of HIV. Investigators have shown that the CNS becomes infected with HIV early during the disease course. Neurobehavioral and neurologic changes occur in the majority of HIV-1 infected individuals. Autopsies have shown evidence of CNS cell damage in 80 to 90 percent of people who die with AIDS. The exact mechanism by which HIV enters the CNS, whether as a free virus and/or via infected cells (e.g., monocyte/macrophages) remains unknown. This RFA is intended to focus attention on investigating the role of the blood-brain barrier (BBB) in HIV neuropathogenesis, with the objective of generating information that will lead to development of therapeutic interventions to prevent the infection and the devastating effects of the virus on the CNS. The blood-brain barrier is an intricate cellular system composed of vascular endothelial cells and perivascular astrocytes that restrict the passage of molecules between the blood stream and the brain parenchyma. The function of this microvascular system is to ensure the proper maintenance of the neuronal microenvironment. This function is accomplished by employing selective transport mechanisms and utilizing tight junctions between neighboring cells to restrict passage of materials. Investigations have detected abnormalities in the human BBB in association with HIV infection. Significantly higher than normal levels of serum proteins (fibrinogen and IgG) were detected in the postmortem brain tissue of HIV-infected individuals as compared to matched seronegative controls. The diffuse leakage into the brain parenchyma, distinct from focal breakdown associated with tissue necrosis, was taken to signify abnormal vascular permeability. Studies have also described similar findings in the post-mortem brain tissue from individuals with AIDS dementia. These observations suggest that abnormal permeability of the BBB is associated with HIV infection. However, the exact role the perturbation of the BBB plays in HIV neuropathogenesis and in disease progression is unclear. For example, one would like to know whether the perturbation of the BBB precedes or succeeds the entry of HIV into the parenchyma. In addition to the brain parenchyma, cerebrospinal fluid (CSF) constitutes the second compartment of the CNS. Investigations have demonstrated that the CSF contains HIV-infected immunocytes throughout the course of the disease. How this and other reported changes in the CSF relate to alterations in the brain parenchyma and vice versa, is poorly understood. It is important that this relationship be defined because the CSF is the only CNS compartment accessible to sampling during life. It can be accessed during the disease progression to facilitate diagnosis, to yield information on the time-course of the CNS disease, and to deliver therapeutic agents. CSF communicates with the blood via the choroid plexus, which shows evidence of HIV infection. Thus, mechanisms underlying communication between the CNS, the CSF, and blood must be better understood to prevent HIV trafficking between these compartments. Areas of Interest The following are examples of research topics pertinent to this RFA to be investigated in humans and/or animal models. This list is not intended to be comprehensive, nor are the examples meant to be exclusive. Researchers responding to this RFA need not limit themselves to these topics; however, a clear linkage of the proposed study to the potential design of therapeutic interventions is desirable. o Define the mechanism(s) by which HIV virions enter, exit, and spread through the CNS. o Identify, characterize, and monitor changes in the BBB associated with HIV infection and disease progression. o Determine whether or not progressive immunodeficiency, caused by HIV, results in changes in the BBB and/or normal trafficking of immunocytes, particularly monocytes. o Determine whether or not HIV infection of circulating monocytes increases the probability of their entry into the CNS. o Identify changes in normal trafficking of immunocytes through the CNS (the brain parenchyma and the CSF) which occur as a result of HIV infection. o Identify and characterize viral-specific and nonspecific mechanisms underlying the perturbation of the BBB occurring during HIV neuropathogenesis. o Characterize potential adverse effects of HIV infection on the development of the BBB. o Develop and characterize in vivo models relevant to this RFA. o Determine changes in the selective passage of substances across the BBB that occur as a result of HIV infection. o Determine whether or not HIV-infected cells traffic from CNS compartments back into circulation. o Characterize functional changes of the choroid plexus associated with HIV infection. o Test neutralization of immunocyte chemoattractants and blocking of cell adhesion molecules (known to facilitate immunocyte trafficking), as means of blocking HIV entry into the CNS. o Determine the impact of current and potential CNS antiretroviral, psychopharmacologic, and other medications on the integrity of the BBB in HIV infection. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results >From the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by May 22, 1995, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the applicatio may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows Institute staff to estimate the potential review workload and avoid conflicts of interest in the review. The letter of intent is to be addressed to Dr. Walter L. Goldschmidts or Dr. A.P. Kerza-Kwiatecki at the addresses listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 594-7248. FIRST (R29) award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title, "Role of Blood Brain Barrier in HIV Neuropathogenesis" (MH-95-003) must be typed on line 2a of the face page of the application form and the YES box must be marked. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC Program Director or Principal Investigator could be included with the application. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive, Room 1040 - MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for courier or express service) At the time of submitssion, two additional copies of the application must be sent to Dr. Walter L. Goldschmidts or Dr. A.P. Kerza-Kwiatecki at the addresses listed under INQUIRIES. Applications must be received by June 27, 1995. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit in accordance with the review criteria stated below, by an appropriate peer review group convened by the NIMH/NINDS. As part of the initial merit review, all applications will receive a written critique and undergo a streamlined (triage) review process in which only those applications deemed to have the highest scientific merit will be discussed, assigned a priority score, and receive a second review by the national advisory council, where applicable. Review Criteria Criteria for scientific/technical merit review of applications are the following: o significance and originality of proposed research from a scientific or technical standpoint; o qualifications and experience of the Principal Investigator and the staff in areas specifically related to the questions under investigation; o adequacy of the conceptual and technical framework for the research, including evidence of familiarity with relevant research literature and proposed techniques; o access to appropriate study population(s), specimens, and equipment; o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated; o adequacy of the existing and proposed facilities and resources; o adequacy of the data analysis plan; o appropriateness of the proposed budget, staffing plan, and time frame in relation to the proposed project. The initial review group will also examine the provisions for the protection of human subjects and the safety of the research environment. AWARD CRITERIA The following criteria will be considered in making funding decision: o scientific merit as determined during the peer review process o availability of funds INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Inquiries regarding programmatic issues may be directed to: Walter L. Goldschmidts, Ph.D. Office on AIDS National Institute of Mental Health Parklawn Building, Room 10-75 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-7281 FAX: (301) 443-9719 Email: wgoldsch@aoamh2.ssw.dhhs.gov A.P. Kerza-Kwiatecki, Ph.D. Division of Demyelination, Atrophic, and Dementing Disorders National Institute of Neurological Disorders and Stroke Federal Building, Room 804 7550 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-1431 FAX: (301) 402-2060 Email: ak45w@nih.gov Ljubisa Vitkovic, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health Parklawn Building, Room 11C-06 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-5288 FAX: (301) 443-4822 Email: lv5g@nih.gov General information on the NIMH AIDS Programs may be obtained from: Ellen Stover, Ph.D. Director, Office on AIDS National Institute of Mental Health Parklawn Building, Room 10-75 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-7281 FAX: (301) 443-9719 Email: estover@aoamh2.ssw.dhhs.gov Direct inquiries regarding fiscal matters to: Ms. Diana S. Trunnell Grants Management Branch National Institute of Mental Health Parklawn Building, Room 7C-14 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-3065 FAX: (301) 443-6885 Email: dt21a@nih.gov Ms. Dianna Jessee Division of Extramural Activities National Institute of Neurological Disorders and Stroke Federal Building, Room 1004 7550 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-9231 FAX: (301) 402-0219 Email: dj35j@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance 93.242, Mental Health Research Grants, and 93,853 and 93,854 Neurological Disorders Grants. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and to promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Mon May 01 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 24, no. 15, pt. 2of3, 28 April 1995 Date: 2 May 1995 09:53:18 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 1499 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <3o5o1u$glp@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19950428 V24N15 P2O3 ************************************ year of support beginning in fiscal year 1996. A total of seven to nine awards are anticipated, pending receipt of applications of sufficient scientific merit and the availability of funds for this purpose. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Etiology and Pathogenesis of Temporomandibular Disorders, is related to the priority area of oral health and the cross-cutting issue of women's health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Governing Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations,, and award criteria for this solicitation may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher@nih.gov), and by mail and email from the program contact listed below. Patricia S. Bryant, PhD Division of Extramural Research National Institute of Dental Research Natcher Building, Room 4AN 18A 45 Center Drive MSC 6402 Bethesda, MD 20892-6402 Telephone: (301) 594-2095 FAX: (301) 480-8318 Email: BryantP@de45.nidr.nih.gov $$R6 END ************************************************************ $$P1 BEGIN PA-95-049 FULL-TEXT ************************************** MENTORED RESEARCH SCIENTIST DEVELOPMENT AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-049 P.T. 34; K.W. 0710030 National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute on Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Environmental Health Sciences National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Institute of Nursing Research National Center for Human Genome Research National Center for Research Resources Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The Mentored Research Scientist Development Award (MRSDA) (K01) is for research scientists who need an additional period of sponsored research experience as a way to gain expertise in a research area new to the candidate or in an area which would demonstrably enhance the candidate's scientific career. It is expected that following this experience, the candidate will be able to pursue an independent and productive research career. The Mentored Research Scientist Development Award (K01) provides an intensive, supervised career development experience in one of the biomedical, behavioral, or clinical sciences. The proposed experience should be in a research area new to the applicant and/or one in which an additional supervised research experience will demonstrably enhance the candidate's scientific career. The experiences should permit the application of novel or highly promising interdisciplinary approaches to particular research problems. Candidates must justify the need for a three, four, or five year period of mentored research experience and must be able to provide a convincing case that the proposed period of support will substantially enhance his/her career and/or will allow the pursuit of a novel or promising approach to a particular research problem. Candidates who have interrupted their careers because of illness or pressing family care commitments may apply if they can clearly demonstrate the potential for productive independent research and the need for an additional period of mentored research experience in order to accomplish an effective scientific reentry. Similarly, faculty members at institutions with a substantial minority enrollment, who wish to enhance their research skills through a supervised research experience at a nearby research center, may also apply, if they agree to remain at their parent institution after completion of the award. The MRSDA replaces four existing NIH career development mechanisms, including the Research Scientist Development Award (K01), the Minority School Faculty Development Award (K14), the Research Career Reentry Program (K17), and the Scientist Development Award (K21). Individuals who were eligible to apply for any one of these awards are now eligible to apply for a K01 award. Therefore, this Program Announcement (PA) supersedes all previous K01, K14, K17, and K21 program announcements. The NIH will no longer accept competing applications for the old K01, K14, K17, and K21 awards. Existing policies and provisions will remain in effect for current K01, K14, K17, and K21 recipients until completion of the non-competing years of their three to five year career development program. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Mentored Research Scientist Development Award, is related to the priority area of human resource development. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contacts listed below. Dr. Robin A. Barr Office of Extramural Affairs National Institute on Aging Gateway Building, Room 2C218, MSC 9205 7201 Wisconsin Avenue Bethesda, MD 20892-9205 Telephone: (301) 496-9322 FAX: (301) 402-9245 Email: Barr@nihniagw.bitnet Dr. Ernestine D. Vanderveen, Ph.D. Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1273 FAX: (301) 594-0673 Email: tvanderv@willco.niaaa.nih.gov Ms. Frances Cotter Division of Clinical and Prevention Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 505 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1207 FAX: (301) 443-8744 Email: fcotter@willco.niaaa.nih.gov Dr. Mary C. Dufour Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 514 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4897 FAX: (301) 443-8614 Email: m.dufour@willco.niaaa.nih.gov Richard Lymn, Ph.D. Extramural Programs National Institute of Arthritis and Musculoskeletal and Skin Diseases Natcher Building, Room 5AS-49E 45 Center Drive, MSC 6500 Bethesda, MD 20892-6500 Telephone: (301) 594-5128 FAX: (301) 480-4543 Email: rl28b@nih.gov The NICHD will accept applications for the K01 under Clinical Rehabilitation Investigator Development Award (CRIDA), but will limit eligibility to candidates who have both clinical training in the rehabilitation related professions (e.g., P.T., O.T., R.N.) and possess doctoral level degrees (e.g., Ph.D., D.Eng., D.Ed.). Individuals supported under CRIDA must be committed to developing careers as independent investigators in medical rehabilitation. Danuta Krotoski, Ph.D. National Center for Medical Rehabilitation Research National Institute of Child Health and Human Development Building 61E, Room 2A03 Bethesda, MD 20892-7510 Telephone: (301) 402-2242 FAX: (301) 402-0832 Email: krotoskd@hd01.nichd.nih.gov Dr. Lester Gorelic Division of Extramural Activities National Cancer Institute Executive Plaza North, Room 643 Bethesda, MD 20892 Telephone: (301) 496-7344 FAX: (301) 402-4551 Email: gorelicl@dea.nci.nih.gov (This award is reserved exclusively for minority faculty development) Dr. Michael Galvin Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, MD 3-02 Research Triangle Park, NC 27709 Telephone: (919) 541-7825 FAX: (919) 541-2843 Email: galvin@niehs.nih.gov National Heart, Lung, and Blood Institute (The NHLBI does not accept applications for the Mentored Research Scientist Award (K01). It does, however, periodically issue Request for Applications (RFA) for the Minority School Faculty Development Award (K01) and the Research Development Award for Minority Faculty (K01) in the NIH Guide for Grants and Contracts.) Dr. Bettie Graham National Center for Human Genome Research Building 38A, Room 610 Bethesda, MD 20892 Telephone: (301) 496-7531 FAX: (301) 480-2770 Email: bg30t@nih.gov George T. Niederehe, Ph.D. Division of Clinical and Treatment Research National Institute of Mental Health 5600 Fishers Lane, Room 18-105 Rockville, MD 20857 Telephone: (301) 443-3264 FAX: (301) 594-6784 Email: gniedere@aoamh4.ssw.dhhs.gov Kenneth G. Lutterman, Ph.D. Division of Epidemiology and Services Research National Institute of Mental Health 5600 Fishers Lane, Room 10-95 Rockville, MD 20857 Telephone: (301) 443-3373 FAX: (301) 443-4045 Email: klutterm@nih.gov Henry Khachaturian, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health 5600 Fishers Lane, Room 11-103 Rockville, MD 20857 Telephone: (301) 443-8033 FAX: (301) 443-1731 Email: hkhach@helix.nih.gov Leonard Mitnick, Ph.D. Office of AIDS Programs National Institute of Mental Health 5600 Fishers Lane, Room 10-75 Rockville, MD 20857 Telephone: (301) 443-9719 FAX: (301) 443-9719 Email: lmitnick@aoamh2.ssw.dhhs.gov Mr. Edward Donohue Division of Extramural Activities National Institute of Neurological Disorders and Stroke Federal Building, Room 1016A Bethesda, MD 20892 Telephone: (301) 496-4188 FAX: (301) 402-4370 Email: ed25b@nih.gov Dr. Mary Lucas Leveck Acute and Chronic Illness Branch National Institute of Nursing Research Building 45, Room 3AN-12 Bethesda, MD 20892-6300 Telephone: (301) 594-5963 FAX: (301) 480-8260 Email: mleveck@ep.ninr.nih.gov Leo A. Whitehair, D.V.M, Ph.D. Comparative Medicine Program National Center for Research Resources Westwood Building, Room 857 Bethesda, MD 20892 Telephone: (301) 435-0746 FAX: (301) 480-3660 Email: leow@ep.ncrr.nih.gov $$P1 END ************************************************************ $$P2 BEGIN PA-95-050 FULL-TEXT ************************************** INDEPENDENT SCIENTIST AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-050 P.T. 34; K.W. 0710030 National Institute on Aging National Institute of Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute Of Arthritis and Musculoskeletal and Skin Diseases National Institute of Child Health and Human Development National Institute of Deafness and Other Communication Disorders National Institute of Dental Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Drug Abuse National Institute of Environmental Health Sciences National Heart, Lung, and Blood Institute National Institute of Mental Health Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The Independent Scientist Award (ISA) (K02) provides support for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. This award is intended to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. This award replaces two existing career development awards including the Research Scientist Development Award (K02) and the Research Career Development Award (K04). Individuals who were eligible to apply for either of these awards are now directed to apply for a K02 award. Therefore, this Program Announcement (PA) supersedes all previous K02 and K04 program announcements. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Independent Scientist Award, is related to the priority area of human resource development. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Dr. Robin A. Barr Office of Extramural Affairs National Institute on Aging Gateway Building, Room 2C218, MSC 9205 7201 Wisconsin Avenue Bethesda, MD 20892-9205 Telephone: (301) 496-9322 FAX: (301) 402-9245 Email: Barr@nihniagw.bitnet Dr. Ernestine D. Vanderveen, Ph.D. Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1273 FAX: (301) 594-0673 Email: tvanderv@willco.niaaa.nih.gov Ms. Frances Cotter Division of Clinical and Prevention Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 505 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1207 FAX: (301) 443-8744 Email: fcotter@willco.niaaa.nih.gov Dr. Mary C. Dufour Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 514 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4897 FAX: (301) 443-8614 Email: m.dufour@willco.niaaa.nih.gov Dr. Milton Hernandez Office of Scientific Training and Manpower Development National Institute of Allergy and Infectious Diseases Solar Building, Room 3C21 Bethesda, MD 20892 Telephone: (301) 496-7291 FAX: (301) 402-0369 Email: mh35c@nih.gov Richard Lymn, Ph.D. Extramural Programs National Institute on Arthritis and Musculoskeletal and Skin Diseases Natcher Building, Room 5AS-49E 45 Center Drive, MSC 6500 Bethesda, MD 20892-6500 Telephone: (301) 594-5128 FAX: (301) 480-4543 Email: rl28b@nih.gov Hildegard Topper Special Assistant to the Deputy Director National Institute of Child Health and Human Development Building 31, Room 2A-03 Bethesda, MD 20892 Telephone: (301) 496-0104 FAX: (301) 402-1104 Email: topperh@hd03.nichd.nih.gov Daniel Sklare, Ph.D. National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400B-13 Bethesda, MD 20892 Telephone: (301) 496-1804 FAX: (301) 402-6251 Email: Daniel_Sklare@nih.gov Dr. James A. Lipton Special Assistant for Training and Career Development National Institute of Dental Research Natcher Building, Room 4AN.18J Bethesda, MD 20892 Telephone: (301) 594-2618 FAX: (301) 480-8319 Email: liptonj@de45.nidr.nih.gov Ronald Margolis, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 5AN-12J MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8819 FAX: (301) 480-3503 Email: margolis@ep.niddk.nih.gov Charles Rodgers, Ph.D. Division of Kidney, Urologic, and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 6AS-19J MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7717 FAX: (301) 480-3510 Email: rodgersc@ep.niddk.nih.gov Timothy P. Condon, Ph.D. OSPEL/SPAB National Institute on Drug Abuse Parklawn Building, Room 10A-55 Telephone: (301) 443-6072 FAX: (301) 443-6277 Email: tc52x@nih.gov Charles W. Sharp, Ph.D. Division of Basic Research National Institute on Drug Abuse Parklawn Building, Room 10A-31 Telephone: (301) 443-1887 FAX: (301) 594-6043 Email: cs107m@nih.gov Arthur Horton, Ed.D. Division of Clinical Research National Institute on Drug Abuse Parklawn Building, Room 10A-30 Telephone: (301) 443-4060 FAX: (301) 443-2317 Email: ah61x@nih.gov Ann Blanken Division of Epidemiology and Prevention Research National Institute on Drug Abuse Parklawn Building, Room 9A-55 Telephone: (301) 443-6543 FAX: (301) 443-9847 Email: ab108v@nih.gov Jamie Biswas, Ph.D. Medications Development Division National Institute on Drug Abuse Parklawn Building, Room 11A-55 Telephone: (301) 443-5280 FAX: (301) 443-2599 Email: jb168r@nih.gov Dr. Michael Galvin Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, MD 3-02 Research Triangle Park, NC 27709 Telephone: (919) 541-7825 FAX: (919) 541-2843 Email: galvin@niehs.nih.gov Thomas Blaszkowski, Ph.D. Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute Federal Building, Room 208A 7550 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-1841 FAX: (301) 480-1455 Email: tb33i@nih.gov Michael Commarato, Ph.D. Division of Heart and Vascular diseases National Heart, Lung, and Blood Institute Federal Building, Room 3C04 7550 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-1724 FAX: (301) 402-2043 Email: mc63a@nih.gov Joyce Creamer Division of Blood diseases and Resources National Heart, Lung, and Blood Institute Federal Building, Room 5C02 7550 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-8388 FAX: (301) 480-0867 Email: jc85n@nih.gov James Kiley, Ph.D. National Center for Sleep Disorders Research National Heart, Lung, and Blood Institute Building 31, Room 4A11 Bethesda, MD 20892 Telephone: (301) 496-7443 FAX: (301) 496-7508 Email: jk52a@nih.gov Mary Reilly Division of Lung Diseases National Heart, Lung, and Blood Institute Westwood Building, Room 640 5333 Westbard Avenue Bethesda, MD 20892 Telephone: (301) 594-7466 FAX: (301) 594-7487 Email: mr50w@nih.gov George T. Niederehe, Ph.D. Division of Clinical and Treatment Research National Institute of Mental Health 5600 Fishers Lane, Room 18-105 Rockville, MD 20857 Telephone: (301) 443-3264 FAX: (301) 594-6784 Email: gniedere@aoamh4.ssw.dhhs.gov Kenneth G. Lutterman, Ph.D. Division of Epidemiology and Services Research National Institute of Mental Health 5600 Fishers Lane, Room 10-95 Rockville, MD 20857 Telephone: (301) 443-3373 FAX: (301) 443-4045 Email: klutterm@aoamh2.ssw.dhhs.gov Henry Khachaturian, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health 5600 Fishers Lane, Room 11-103 Rockville, MD 20857 Telephone: (301) 443-8033 FAX: (301) 443-1731 Email: hkhach@helix.nih.gov Leonard Mitnick, Ph.D. Office of AIDS Programs National Institute of Mental Health 5600 Fishers Lane, Room 10-75 Rockville, MD 20857 Telephone: (301) 443-9719 FAX: (301) 443-9719 Email: lmitnick@aoamh2.ssw.dhhs.gov $$P2 END ************************************************************ $$P3 BEGIN PA-95-051 FULL-TEXT ************************************** SENIOR SCIENTIST AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-051 P.T. 34; K.W. 0710030 National Institute on Alcoholism and Alcohol Abuse National Institute on Drug Abuse National Institute of Mental Health Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The Senior Scientist Award (K05) provides stability of support to outstanding scientists who have demonstrated a sustained, high level of productivity and whose expertise, research accomplishments, and contributions to the field have been and will continue to be critical to the mission of the particular NIH center or institute. The award provides salary support for award periods of five years as a means of enhancing the individual recipient's skills and dedication to his/her area of research. The Senior Scientist Award (K05) permits NIH institutes and centers to identify and support exceptionally talented investigators who are well established in their field of research. Since not all of the NIH institutes and centers support this award, potential applicants should contact the appropriate NIH program staff listed under INQUIRIES prior to preparing an application. The NIH recently reviewed the career awards (K-series) used to develop the research capabilities of clinicians and other scientists needed to carry out the nation's research mission in the biomedical and behavioral sciences. This evaluation resulted in several changes: (1) the total number of K mechanisms were reduced from 19 to six; (2) the review criteria were refined to clarify the career development goals of the K award; and (3) K award applications will be assigned to initial review groups managed by the prospective funding institute or center to which the application has been assigned. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Senior Scientist Award, is related to the priority area of human resource development. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Dr. Ernestine D. Vanderveen, Ph.D. Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1273 FAX: (301) 594-0673 Email: tvanderv@willco.niaaa.nih.gov Ms. Frances Cotter Division of Clinical and Prevention Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 505 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1207 FAX: (301) 443-8744 Email: fcotter@willco.niaaa.nih.gov Dr. Mary C. Dufour Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 514 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4897 FAX: (301) 443-8614 Email: m.dufour@willco.niaaa.nih.gov Timothy P. Condon, Ph.D. Office of Science Policy, Education, and Legislation National Institute on Drug Abuse Parklawn Building, Room 10A-55 Rockville, MD 20857 Telephone: (301) 443-6072 FAX: (301) 443-6277 Email: tc52x@nih.gov Charles W. Sharp, Ph.D. Division of Basic Research National Institute on Drug Abuse Parklawn Building, Room 10A-31 Rockville, MD 20857 Telephone: (301) 443-1887 FAX: (301) 594-6043 Email: cs107m@nih.gov Arthur Horton, Ed.D. Division of Clinical Research National Institute on Drug Abuse Parklawn Building, Room 10A-30 Rockville, MD 20857 Telephone: (301) 443-4060 FAX: (301) 443-2317 Email: ah61x@nih.gov Ann Blanken Division of Epidemiology and Prevention Research National Institute on Drug Abuse Parklawn Building, Room 9A-55 Rockville, MD 20857 Telephone: (301) 443-6543 FAX: (301) 443-9847 Email: ab108v@nih.gov Jamie Biswas, Ph.D. Medications Development Division National Institute on Drug Abuse Parklawn Building, Room 11A-55 Rockville, MD 20857 Telephone: (301) 443-5280 FAX: (301) 443-2599 Email: jb168r@nih.gov George T. Niederehe, Ph.D. Division of Clinical and Treatment Research National Institute of Mental Health 5600 Fishers Lane, Room 18-105 Rockville, MD 20857 Telephone: (301) 443-3264 FAX: (301) 594-6784 Email: gniedere@aoamh4.ssw.dhhs.gov Kenneth G. Lutterman, Ph.D. Division of Epidemiology and Services Research National Institute of Mental Health 5600 Fishers Lane, Room 10-95 Rockville, MD 20857 Telephone: (301) 443-3373 FAX: (301) 443-4045 Email: klutterm@nih.gov Henry Khachaturian, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health 5600 Fishers Lane, Room 11-103 Rockville, MD 20857 Telephone: (301) 443-8033 FAX: (301) 443-1731 Email: hkhach@helix.nih.gov Leonard Mitnick, Ph.D. Office of AIDS Programs National Institute of Mental Health 5600 Fishers Lane, Room 10-75 Rockville, MD 20857 Telephone: (301) 443-9719 FAX: (301) 443-9719 Email: lmitnick@aoamh2.ssw.dhhs.gov $$P3 END ************************************************************ $$P4 BEGIN PA-95-052 FULL-TEXT ************************************** ACADEMIC CAREER AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-052 P.T. 34; K.W. 0710030 National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Environmental Health Sciences National Institute of Mental Health Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The Academic Career Award (K07) is used by the NIH Institutes and Centers to support individuals interested in introducing or improving curriculum in a particular scientific field as a means of enhancing the educational or research capacity at the grantee institution. Since not all of the NIH Institutes and Centers offer this award, potential applicants should contact the appropriate NIH program staff listed under INQUIRIES, prior to preparing an application. This Academic Career Award (K07) supports two types of activities: Development. The K07 provides support for more junior candidates who are interested in developing an academic and research expertise in a particular field, as a way to increase the overall pool of individuals capable of research or teaching in the identified area. During the period of the award, the candidate will become a successful academician in the chosen area. Teaching, curriculum building, research, and leadership skills are to be learned during the tenure of the award. For junior candidates, a mentor is required. Leadership. The K07 also supports more senior individuals with acknowledged scientific expertise and leadership skills who are interested in improving the curricula and enhancing the research capacity within an academic institution. It is expected that support under this award will increase the visibility and the overall research support or academic capacity for the given field of research within the academic medical/health and research community. Not all of the NIH awarding components support the K07 or both components of this award. For example, the National Institute of Mental Health does not support the leadership component of this award. Applicants are strongly encouraged to contact the prospective NIH awarding component prior to preparing an application. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Academic Career Award, is related to the priority area of human resource development. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Dr. Robin A. Barr Office of Extramural Affairs National Institute on Aging Gateway Building, Room 2C218, MSC 9205 7201 Wisconsin Avenue Bethesda, MD 20892-9205 Telephone: (301) 496-9322 FAX: (301) 402-9245 Email: Barr@nihniagw.bitnet Dr. Ernestine D. Vanderveen, Ph.D. Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1273 FAX: (301) 594-0673 Email: tvanderv@willco.niaaa.nih.gov Ms. Frances Cotter Division of Clinical and Prevention Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 505 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1207 FAX: (301) 443-8744 Email: fcotter@willco.niaaa.nih.gov Dr. Mary C. Dufour Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 514 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4897 FAX: (301) 443-8614 Email: m.dufour@willco.niaaa.nih.gov Richard Lymn, Ph.D. Extramural Programs National Institute on Arthritis and Musculoskeletal and Skin Diseases Natcher Building, Room 5AS-49E MSC 6500 Bethesda, MD 20892-6500 Telephone: (301) 594-5128 FAX: (301) 480-4543 Email: rl28b@nih.gov Dr. John Schneider or Dr. Andrew Vargosko Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 520 Bethesda, MD 20892 Telephone: (301) 496-8580 FAX: (301) 402-4472 Email: schneidj@dcbdcep.nci.nih.gov Email: vargoska@dcbdcep.nci.nih.gov Dr. Annette Kirshner Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, MD 3-03 Research Triangle Park, NC 27709 Telephone: (919) 541-0488 FAX: (919) 541-2843 Email: kirshner@niehs.nih.gov National Heart, Lung, and Blood Institute (The NHLBI does not accept applications for the Academic Career Award on a regular basis. It does, however, issue Requests for Applications (RFAs) using this award as programmatic needs arise.) George T. Niederehe, Ph.D. Division of Clinical and Treatment Research National Institute of Mental Health 5600 Fishers Lane, Room 18-105 Rockville, MD 20857 Telephone: (301) 443-3264 FAX: (301) 594-6784 Email: gniedere@aoamh4.ssw.dhhs.gov $$P4 END ************************************************************ $$P5 BEGIN PA-95-053 FULL-TEXT ************************************** MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-053 P.T. 34; K.W. 0710030, 0785035 National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Child Health and Human Development National Institute on Deafness and Other Communication Disorders National Institute of Dental Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Drug Abuse National Institute of Environmental Health Sciences National Eye Institute National Heart, Lung, and Blood Institute National Institute of Mental Health National Institute of Neurological Disorders and Stroke Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The purpose of the Mentored Clinical Scientist Development Award (MCSDA) (K08) is to support the development of outstanding clinician research scientists. This mechanism provides specialized study for clinically trained professionals who are committed to a career in research and have the potential to develop into independent investigators. The award supports a three, four, or five year period of supervised research experience that may integrate didactic studies with laboratory or clinically-based research. The proposed research should have both intrinsic research importance and be a suitable vehicle for learning the methodology, theories, and conceptualizations necessary for a well trained independent researcher. Because of the focus on progression to independence, the prospective candidate should propose a period of study and development consistent with this goal and his or her previous research and clinical experience. For example, a candidate with limited experience in a given field of research may find a phased developmental program lasting for five years that includes a designated period of didactic training and supervised research experience the most efficient means of attaining independence. A candidate with substantial previous research experience may require a shorter award period appropriate for the transition to independence. The entire program should be comparable in scope and rigor to meeting the requirements for an advanced research degree. This award replaces the Clinical Investigator Award (K08), the Physician Scientist Award (K11), the Dentist Scientist Award (K15), and the Scientist Development Award for Clinicians (K20). Individuals who were eligible to apply for one of these awards are now directed to apply for an MCSDA. Therefore, this program Announcement supersedes all previous K08, K11, K15 and K20 program announcements and competing applications for these awards will no longer be accepted. Existing policies and provisions will remain in effect for current K08, K11, K15 and K20 recipients until completion of the non-competing years of their career development program. The NIH institutes and centers implement this award in different ways to accommodate the career needs of researchers in fields within their missions. For example the National Institute of Dental Research (NIDR) requires that, in most situations, candidates must pursue a program that includes didactic and supervised basic or behavioral science research experiences which result in the Ph.D. degree. The NIDR may, under specific circumstances, provide support under this program for the development of advanced clinical knowledge and skills in either a recognized clinical specialty or equivalent dental clinical discipline. Therefore, the prospective candidate must have a D.D.S. or an equivalent degree but need not have started postgraduate training, such as in a clinical specialty or general practice dental residency. However, preference will be given to applicants with advanced training in general or specialty practice. Dentists without advanced clinical knowledge and skills are eligible for the MCSDA but are encouraged to seek appointments to the Mentored Clinical Scientist Development Program Award (K12). All applicants are strongly encouraged to contact the prospective awarding component to discuss issues of eligibility and the specific provisions of this award. The NIH recently reviewed its career awards (K) used to develop the research capabilities of clinicians and other scientists needed to carry out the nation's research mission in the biomedical and behavioral sciences. This evaluation resulted in several changes: (1) the total number of K mechanisms were reduced from 19 to six; (2) the review criteria were refined to clarify the career development goals of the K award; and (3) K award applications will be assigned to initial review groups managed by the prospective funding institute or center to which the application has been assigned. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This program announcement, Mentored Clinical Scientist Development Award, is related to the priority area of human resource development. Potential candidates may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Dr. Robin A. Barr Office of Extramural Affairs National Institute on Aging 7201 Wisconsin Avenue, Room 2C218, MSC 9205 Bethesda, MD 20892-9205 Telephone: (301) 496-9322 FAX: (301) 402-9245 Email: Barr@nihniagw.bitnet Dr. Ernestine D. Vanderveen, Ph.D. Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1273 FAX: (301) 594-0673 Email: tvanderv@willco.niaaa.nih.gov Ms. Frances Cotter Division of Clinical and Prevention Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 505 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-1207 FAX: (301) 443-8744 Email: fcotter@willco.niaaa.nih.gov Dr. Mary C. Dufour Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 514 MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4897 FAX: (301) 443-8614 Email: m.dufour@willco.niaaa.nih.gov Dr. Milton Hernandez Office of Scientific Training and Manpower Development National Institute of Allergy and Infectious Diseases Solar Building, Room 3C21 Bethesda, MD 20892 Telephone: (301) 496-7291 FAX: (301) 402-0369 Email: mh35c@nih.gov Richard Lymn, Ph.D. Extramural Programs National Institute on Arthritis and Musculoskeletal and Skin Diseases 45 Center Drive, Room 5AS-49E MSC 6500 Bethesda, MD 20892-6500 Telephone: (301) 594-5128 FAX: (301) 480-4543 Email: rl28b@nih.gov Dr. John Schneider or Dr. Andrew Vargosko Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 520 Bethesda, MD 20892 Telephone: (301) 496-8580 FAX: (301) 402-4472 Email: schneidj@dcbdcep.nci.nih.gov or vargoska@dcbdcep.nci.nih.gov Hildegard Topper Special Assistant to the Deputy Director National Institute of Child Health and Human Development Building 31, Room 2A-03 Bethesda, MD 20892 Telephone: (301) 496-0104 FAX: (301) 402-1104 Email: topperh@hd03.nichd.nih.gov Daniel Sklare, Ph.D. National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400B-13 Bethesda, MD 20892 Telephone: (301) 496-1804 FAX: (301) 402-6251 Email: Daniel_Sklare@nih.gov Dr. James A. Lipton Special Assistant for Training and Career Development National Institute of Dental Research Natcher Building, Room 4AN.18J Bethesda, MD 20892 Telephone: (301) 594-2618 FAX: (301) 480-8319 Email: liptonj@de45.nidr.nih.gov Ronald Margolis, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 5AN-12J, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8819 FAX: (301) 480-3503 Email: margolis@ep.niddk.nih.gov Charles Rodgers, Ph.D. Division of Kidney, Urologic, and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 6AS-19J MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7717 FAX: (301) 480-3510 Email: rodgersc@ep.niddk.nih.gov Judith Podskalny, Ph.D. Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 6AN-12E, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8876 FAX: (301) 480-8300 Email: podskalnyj@ep.niddk.nih.gov Timothy P. Condon, Ph.D. Office of Science Policy, Education, and Legislation National Institute on Drug Abuse Parklawn Building, Room 10A-55 Rockville, MD 20857 Telephone: (301) 443-6072 FAX: (301) 443-6277 Email: tc52x@nih.gov Charles W. Sharp, Ph.D. Division of Basic Research National Institute on Drug Abuse Parklawn Building, Room 10A-31 Rockville, MD 20857 Telephone: (301) 443-1887 FAX: (301) 594-6043 Email: cs107m@nih.gov Arthur Horton, Ed.D. Division of Clinical Research National Institute on Drug Abuse Parklawn Building, Room 10A-30 Rockville, MD 20857 Telephone: (301) 443-4060 FAX: (301) 443-2317 Email: ah61x@nih.gov Ann Blanken Division of Epidemiology and Prevention Research National Institute on Drug Abuse Parklawn Building, Room 9A-55 Rockville, MD 20857 Telephone: (301) 443-6543 FAX: (301) 443-9847 Email: ab108v@nih.gov Jamie Biswas, Ph.D. Medications Development Division National Institute on Drug Abuse Parklawn Building, Room 11A-55 Rockville, MD 20857 Telephone: (301) 443-5280 FAX: (301) 443-2599 Email: jb168r@nih.gov Dr. Michael Galvin Division of Extramural Research and Training National Institute of Environmental Health Sciences P.O. Box 12233, MD 3-02 Research Triangle Park, NC 27709 Telephone: (919) 541-7825 FAX: (919) 541-2843 Email: galvin@niehs.nih.gov Dr. Maria Giovanni National Eye Institute Building 31, Room 6A48 Bethesda, MD 20892 Telephone: (301) 496-0484 FAX: (301) 402-0528 Email: mg37u@nih.gov Thomas Blaszkowski, Ph.D. Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute Federal Building, Room 208A Bethesda, MD 20892 Telephone: (301) 496-1841 FAX: (301) 480-1455 Email: tb33i@nih.gov Michael Commarato, Ph.D. Division of Heart and Vascular diseases National Heart, Lung, and Blood Institute 7550 Wisconsin Avenue, Room 3C04 Bethesda, MD 20892 Telephone: (301) 496-1724 FAX: (301) 402-2043 Email: mc63a@nih.gov Joyce Creamer Division of Blood diseases and Resources National Heart, Lung, and Blood Institute 7550 Wisconsin Avenue, Room 5C02 Bethesda, MD 20892 Telephone: (301) 496-8388 FAX: (301) 480-0867 Email: jc85n@nih.gov James Kiley, Ph.D. National Center for Sleep Disorders Research National Heart, Lung, and Blood Institute Building 31, Room 4A11 Bethesda, MD 20892 Telephone: (301) 496-7443 FAX: (301) 496-7508 Email: jk52a@nih.gov Mary Reilly Division of Lung Diseases National Heart, Lung, and Blood Institute Westwood Building, Room 640 Bethesda, MD 20892 Telephone: (301) 594-7466 FAX: (301) 594-7487 Email: mr50w@nih.gov George T. Niederehe, Ph.D. Division of Clinical and Treatment Research National Institute of Mental Health 5600 Fishers Lane, Room 18-105 Rockville, MD 20857 Telephone: (301) 443-3264 FAX: (301) 594-6784 Email: gniedere@aoamh4.ssw.dhhs.gov Kenneth G. Lutterman, Ph.D. Division of Epidemiology and Services Research National Institute of Mental Health 5600 Fishers Lane, Room 10-95 Rockville, MD 20857 Telephone: (301) 443-3373 FAX: (301) 443-4045 Email: klutterm@nih.gov Henry Khachaturian, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health 5600 Fishers Lane, Room 11-103 Rockville, MD 20857 Telephone: (301) 443-8033 Email: hkhach@helix.nih.gov Leonard Mitnick, Ph.D. Office of AIDS Programs National Institute of Mental Health 5600 Fishers Lane, Room 10-75 Rockville, MD 20857 Telephone: (301) 443-9719 Email: lmitnick@aoamh2.ssw.dhhs.gov Mr. Edward Donohue Division of Extramural Activities National Institute of Neurological Disorders and Stroke Federal Building, Room 1016A Bethesda, MD 20892 Telephone: (301) 496-4188 Email: ed25b@nih.gov $$P5 END ************************************************************ $$P6 BEGIN PA-95-054 FULL-TEXT ************************************** MENTORED CLINICAL SCIENTIST DEVELOPMENT PROGRAM AWARD NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-054 P.T. 34; K.W. 0710030, 0785035 National Institute on Aging National Institute of Dental Research Application Receipt Dates: February 1, June 1, and October 1 PURPOSE The Mentored Clinical Scientist Development Program Award (MCSDPA) (K12) is an award to an educational institution to support career development experiences for clinicians leading to research independence. Under this award, newly-trained clinicians are to be selected and appointed to this program award by the grantee institution. In other respects, the research experience of the candidates selected for support under this award should resemble those supported by the individual Mentored Clinical Scientist Development Award. Applications for this award should propose a research plan that has both intrinsic research importance and will also serve as a suitable vehicle for learning the methodology, theories, and conceptualizations necessary for a well trained independent researcher. The program should be designed to accommodate appointees with varying levels of experiences. For example, a prospective candidate with limited experience in a given field of research may find it appropriate to engage in a structured, phased developmental program, including a designated period of didactic training followed by a period of supervised research experience. The entire program should be comparable in scope and rigor to meeting the requirements for an advanced research degree. The NIH institutes and centers have modified this award to accommodate the career pathways of researchers in fields related to their missions. For example, the National Institute of Dental Research (NIDR) requires that all candidates must pursue a program that includes didactic and supervised basic or behavioral research experiences that result in the Ph.D. degree. The NIDR provides support under this program for the development of advanced clinical knowledge and skills in either a recognized clinical specialty or equivalent dental clinical discipline. Therefore, the prospective candidate must have a D.D.S. or an equivalent degree but need not have started postgraduate training, such as in a clinical specialty. Dentists who already posses advanced clinical knowledge and skills are eligible for the MCSDPA under special circumstances, but are encouraged to seek appointments to the Mentored Clinical Scientist Development Award (K08). All applicants and potential appointees are strongly advised to contact the prospective NIH awarding component for information about eligibility and the specific provisions of this award. This award replaces two comparable NIH career development program awards for clinicians. These are the Physician Scientist Program Award (K12) and the Dentist Scientist Program Award (K16). Institutions and departments that were eligible to apply for either of these program awards are now eligible to apply for the MCSDPA award. Therefore, this program announcement supersedes all previous K12 and K16 program announcements. The NIH will no longer accept competing applications for the old K12 and K16 awards. The new MCSDPA has been modified to incorporate the features of these career development programs. Existing policies and provisions will remain in effect for current K12 and K16 awards until completion of their non-competing years. The NIH recently reviewed its career awards (K-series) used to develop the research capabilities of clinicians and other scientists needed to carry out the nation's research mission in the biomedical and behavioral sciences. This evaluation resulted in several changes: (1) the total number of K mechanisms were reduced from 19 to six; (2) the review criteria were refined to clarify the career development goals of the K award; and (3) K award applications will be assigned to initial review groups managed by the prospective funding institute or center to which the application has been assigned. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Mentored Clinical Scientist Development Program Award, is related to the priority area of human resource development. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Dr. Robin A. Barr Office of Extramural Affairs National Institute on Aging 7201 Wisconsin Avenue, Room 2C218, MSC 9205 Bethesda, MD 20892-9205 Telephone: (301) 496-9322 Email: Barr@nihniagw.bitnet Dr. James A. Lipton Special Assistant for Training and Career Development National Institute of Dental Research Natcher Building, Room 4AN.18J Bethesda, MD 20892 Telephone: (301) 594-2618 Email: liptonj@de45.nidr.nih.gov $$P6 END ************************************************************ $$P7 BEGIN PA-95-055 FULL-TEXT ************************************** RESEARCH ON COMORBID MENTAL AND DRUG ABUSE DISORDERS NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-055 P.T. 34; K.W. 0715129, 0404009, 0755030, 0715008, 0745027 National Institute on Drug Abuse National Institute of Mental Health PURPOSE The purpose of this program announcement is to encourage research on comorbid mental and drug abuse disorders. One aim of this research program is to explore and identify etiological and neurobiological factors that are associated with the co-occurrence of drug abuse/addiction and mental disorders. A second aim is to develop new treatment and prevention interventions for the population afflicted with these disorders. A third aim is to develop effective strategies and procedures for managing the impact of HIV/AIDS on individuals with comorbid mental and addictive disorders and the impact of comorbid mental and addictive disorders on persons with HIV/AIDS. A fourth aim is to assess existing drug abuse and mental health treatment interventions and services for persons with mental and addictive disorders. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement, Research on Comorbid Mental and Drug Abuse Disorders, is primarily related to the priority area of alcohol and other drugs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contacts listed below. Arthur MacNeill Horton, Jr., Ed.D. Division of Clinical and Services Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-46 Rockville, MD 20857 Telephone: (301) 443-6697 Email: ah61x@nih.gov Kathryn M. Magruder, M.P.H., Ph.D. Division of Epidemiology and Services Research National Institute of Mental Health 5600 Fishers Lane, Room 10C-06 Rockville, MD 20857 Telephone: (301) 443-3364 Email: kmagrude@aoamh2.ssw.dhhs.gov $$P7 END ************************************************************ $$P8 BEGIN PA-95-056 FULL-TEXT ************************************** BIOBEHAVIORAL PAIN RESEARCH NIH GUIDE, Volume 24, Number 15, April 28, 1995 PA AVAILABLE: PA-95-056 From owner-sci-resources@net.bio.net Mon May 01 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 24, no. 15, pt. 1of3, 28 April 1995 Date: 2 May 1995 09:53:08 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 1499 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <3o5o1k$glc@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19950428 V24N15 P1O3 ************************************ X-comment: RFAS described: MH-95-003, CA-95-012, DE-95-002, PA-95-049, PA-95- 050, PA-95-051, PA-95-052, PA-95-053, PA-95-054, P A-95-055, PA-95-056 NIH GUIDE - Vol. 24, No. 15 - April 28, 1995 $$INDEX BEGIN ******************************************************* NOTICES $$INDEX N1 ********************************************************** REVISION OF NIH CAREER DEVELOPMENT GRANT MECHANISMS National Institutes of Health INDEX: NATIONAL INSTITUTES OF HEALTH $$INDEX N2 ********************************************************** FY 95 FUNDING MECHANISMS FOR THE NATIONAL ACTION PLAN ON BREAST CANCER National Cancer Institute INDEX: CANCER $$INDEX N3 ********************************************************** COMMONLY ASKED QUESTIONS ABOUT EQUIPMENT UNDER GRANTS National Institutes of Health INDEX: NATIONAL INSTITUTES OF HEALTH $$INDEX N4 ********************************************************** GUIDELINES ON INCLUSION OF WOMEN, MINORITIES, AND PERSONS WITH DISABILITIES IN NIH SPONSORED AND/OR SUPPORTED INTRAMURAL AND EXTRAMURAL SCIENTIFIC MEETINGS AND CONFERENCES National Institutes of Health INDEX: NATIONAL INSTITUTES OF HEALTH NOTICES OF AVAILABILITY (RFPs/RFAs/PAs) $$INDEX R1 ********************************************************** CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS (RFP NIH-NIAID-DAIDS-96-14) National Institute of Allergy and Infectious Diseases INDEX: ALLERGY, INFECTIOUS DISEASES $$INDEX R2 ********************************************************** SYNTHESIS OF BULK CHEMICALS AND DRUGS FOR PRECLINICAL AND CLINICAL STUDIES (RFP NCI-CM-57238-30) National Cancer Institute INDEX: CANCER $$INDEX R3 ********************************************************** PREPARATION OF GONADAL CELLS AND CELL FRACTIONS (RFP NICHD-IRP-95-15) National Institute of Child Health and Human Development INDEX: CHILD HEALTH, HUMAN DEVELOPMENT $$INDEX R4 06/27/95 ************************************************* ROLE OF THE BLOOD BRAIN BARRIER IN HIV NEUROPATHOGENESIS (RFA MH-95-003) National Institute of Mental Health National Institute of Neurological Disorders and Stroke INDEX: MENTAL HEALTH; NEUROLOGICAL DISORDERS, STROKE $$INDEX R5 10/20/95 ************************************************* INVESTIGATOR GRANTS FOR CLINICAL CANCER THERAPY RESEARCH (RFA CA-95-012) National Cancer Institute INDEX: CANCER $$INDEX R6 10/24/95 ************************************************* ETIOLOGY AND PATHOGENESIS OF TEMPOROMANDIBULAR DISORDERS (RFA DE-95-002) National Institute of Dental Research Office of Research on Women's Health INDEX: DENTAL RESEARCH; WOMEN'S HEALTH $$INDEX P1 ********************************************************** MENTORED RESEARCH SCIENTIST DEVELOPMENT AWARD (PA-95-049) National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Environmental Health Sciences National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Institute of Nursing Research National Center for Human Genome Research National Center for Research Resources INDEX: AGING; ALCOHOL ABUSE, ALCOHOLISM; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; CANCER; ENVIRONMENTAL HEALTH SCIENCES; MENTAL HEALTH; NEUROLOGICAL DISORDERS, STROKE; NURSING; HUMAN GENOME; RESEARCH RESOURCES $$INDEX P2 ********************************************************** INDEPENDENT SCIENTIST AWARD (PA-95-050) National Institute on Aging National Institute of Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Child Health and Human Development National Institute on Deafness and Other Communication Disorders National Institute of Dental Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Drug Abuse National Institute of Environmental Health Sciences National Heart, Lung, and Blood Institute National Institute of Mental Health INDEX: AGING; ALCOHOL ABUSE, ALCOHOLISM; ALLERGY, INFECTIOUS DISEASES; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; CHILD HEALTH, HUMAN DEVELOPMENT; DEAFNESS, OTHER COMMUNICATION DISORDERS; DENTAL RESEARCH; DIABETES, DIGESTIVE, KIDNEY DISEASES; DRUG ABUSE; ENVIRONMENTAL HEALTH SCIENCES; HEART, LUNG, BLOOD; MENTAL HEALTH $$INDEX P3 ********************************************************** SENIOR SCIENTIST AWARD (PA-95-051) National Institute on Alcohol Abuse and Alcoholism National Institute on Drug Abuse National Institute of Mental Health INDEX: ALCOHOL ABUSE, ALCOHOLISM; DRUG ABUSE; MENTAL HEALTH $$INDEX P4 ********************************************************** ACADEMIC CAREER AWARD (PA-95-052) National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Environmental Health Sciences National Institute of Mental Health INDEX: AGING; ALCOHOL ABUSE, ALCOHOLISM; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; CANCER; ENVIRONMENTAL HEALTH SCIENCES; MENTAL HEALTH $$INDEX P5 ********************************************************** MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD (PA-95-053) National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Child Health and Human Development National Institute on Deafness and Other Communication Disorders National Institute of Dental Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Drug Abuse National Institute of Environmental Health Sciences National Eye Institute National Heart, Lung, and Blood Institute National Institute of Mental Health National Institute of Neurological Disorders and Stroke INDEX: AGING; ALCOHOL ABUSE, ALCOHOLISM; ALLERGY, INFECTIOUS DISEASES; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; CANCER; CHILD HEALTH, HUMAN DEVELOPMENT; DEAFNESS, OTHER COMMUNICATION DISORDERS; DENTAL RESEARCH; DIABETES, DIGESTIVE, KIDNEY DISEASES; DRUG ABUSE; ENVIRONMENTAL HEALTH SCIENCES; EYE; HEART, LUNG, BLOOD; MENTAL HEALTH; NEUROLOGICAL DISORDERS, STROKE $$INDEX P6 ********************************************************** MENTORED CLINICAL SCIENTIST DEVELOPMENT PROGRAM AWARD (PA-95-054) National Institute on Aging National Institute of Dental Research INDEX: AGING; DENTAL RESEARCH $$INDEX P7 ********************************************************** RESEARCH ON COMORBID MENTAL AND DRUG ABUSE DISORDERS (PA-95-055) National Institute on Drug Abuse National Institute of Mental Health INDEX: DRUG ABUSE; MENTAL HEALTH $$INDEX P8 ********************************************************** BIOBEHAVIORAL PAIN RESEARCH (PA-95-056) National Institute of Nursing Research National Institute of Dental Research National Institute on Aging National Institute of Arthritis and Musculoskeletal and Skin Diseases National Cancer Institute National Institute of Child Health and Human Development National Institute on Drug Abuse National Heart, Lung, and Blood Institute National Institute of Mental Health National Institute of Neurological Disorders and Stroke Office of Alternative Medicine INDEX: NURSING; DENTAL RESEARCH; AGING; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; CANCER; CHILD HEALTH, HUMAN DEVELOPMENT; DRUG ABUSE; HEART, LUNG, BLOOD; MENTAL HEALTH; NEUROLOGICAL DISORDERS, STROKE; ALTERNATIVE MEDICINE THIS PUBLICATION IS AVAILABLE ELECTRONICALLY VIA BITNET OR INTERNET, BY SUBSCRIPTION, AND IS ALSO ON THE NIH GOPHER (GOPHER.NIH.GOV). ALTERNATIVE ACCESS IS THROUGH THE NIH GRANT LINE USING A PERSONAL COMPUTER (DATA LINE 301/402-2221); CONTACT DR. JOHN JAMES AT 301/594- 7270 FOR DETAILS. THE PHS STRONGLY ENCOURAGES ALL GRANT AND CONTRACT RECIPIENTS TO PROVIDE A SMOKE-FREE WORKPLACE AND PROMOTE THE NON-USE OF ALL TOBACCO PRODUCTS. IN ADDITION, PUBLIC LAW 103-227, THE PRO-CHILDREN ACT OF 1994, PROHIBITS SMOKING IN CERTAIN FACILITIES (OR IN SOME CASES, ANY PORTION OF A FACILITY) IN WHICH REGULAR OR ROUTING EDUCATION, LIBRARY, DAY CARE, HEALTH CARE OR EARLY CHILDHOOD DEVELOPMENT SERVICES ARE PROVIDED TO CHILDREN. THIS IS CONSISTENT WITH THE PHS MISSION TO PROTECT AND ADVANCE THE PHYSICAL AND MENTAL HEALTH OF THE AMERICAN PEOPLE. $$INDEX END ********************************************************* NOTICES $$N1 BEGIN ********************************************************** REVISION OF NIH CAREER DEVELOPMENT GRANT MECHANISMS NIH GUIDE, Volume 24, Number 15, April 28, 1995 P.T. 34; K.W. 1014006 National Institutes of Health The program announcements that follow in this edition of the NIH Guide for Grants and Contracts describe the six new career development grant mechanisms (K-series) that replace the 14 previous awards. The new grant mechanisms have been developed to streamline the system of career awards. They do not change the instructions for preparing career award applications as described in the Research Career Development Awards section of the Public Health Service (PHS) Grant Application Form (Form PHS 398) nor do they appreciably change the eligibility of individuals for career award support. They do, however, simplify the career grant options so that prospective applicants can more easily understand how these awards mesh with their own career goals and can be used to enhance the development of their research skills. The new awards are organized by career level, the type of previous training, and whether a mentor is required. For example, the Mentored Clinical Scientists Development Award (K08) provides support for individuals with health-professional degrees who require an intensive, supervised research experience that will lead to independence as a researcher. This award replaces four awards with comparable provisions: the Clinical Investigator Award (K08), the Physician Scientist Award (K11), the Dental Scientist Award (K15), and the Scientist Development Award for Clinicians (K20). The program announcement for the Mentored Clinical Scientist Development Award (K08) will provide applicants with general information about application characteristics and review criteria that are common across most of the NIH Institutes and Centers (ICs). Prospective applicants are advised, however, that some of the new awards are not supported by all of the ICs, some of the ICs selectively encourage career development in specific fields or for individuals with previous training in specialized areas, and some of the ICs offer different award provisions such as salary and research expenses. In some cases, an IC will issue a separate program announcement (PA) or request for applications (RFA) to describe the specific provisions or intent of their award. Accordingly, applicants are strongly encouraged to examine the list of participating NIH institutes and centers for each program announcement and to make contact with one of the individuals listed at under the INQUIRIES section of each program announcement, prior to developing an application. The new awards are organized as follows: o MENTORED RESEARCH SCIENTIST DEVELOPMENT AWARD (K01)--an award to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area which would demonstrably enhance the applicant's scientific career. This award is generally reserved for individuals interested in switching to a new research field, for individuals who have interrupted their career because of illness or pressing family care responsibilities, or for faculty at minority institutions who wish to enhance their capacity for independent research. This proposed mechanism replaces the K01, K14, K17 and K21 mechanisms. o INDEPENDENT SCIENTIST AWARD (K02)--an award to support recently independent scientists with outstanding potential to become future leaders in biomedical, behavioral or clinical sciences. This proposed mechanism replaces the K02 and the K04 mechanisms. o SENIOR SCIENTIST AWARD (K05)--an award to support senior scientists who are recognized leaders in the field. This mechanism is the same as the K05 mechanism. o ACADEMIC CAREER AWARD (K07)--an award to support individuals who wish to develop expertise in a specific academic area or to support acknowledged experts to develop curricula and research capacity within an academic institution. This mechanism is the same as the current K07. o MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD (K08)--an individual award for clinicians who need an intensive period of mentored research experience. This proposed mechanism replaces the K08, K11, K15 and K20 mechanisms. o MENTORED CLINICAL SCIENTIST DEVELOPMENT PROGRAM AWARD (K12)--the program variant of the K08. This award replaces the K12 and K16 mechanisms. As mentioned above, not all of the NIH ICs participate in a regular basis in each of these awards. The following is a listing of the currently participating ICs: o MENTORED RESEARCH SCIENTIST DEVELOPMENT AWARD (K01) -- National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Center for Human Genome Research, National Center for Research Resources o INDEPENDENT SCIENTIST AWARD (K02) -- National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute on Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Deafness and Other Communication Disorders, National Institute of Dental Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Heart, Lung, and Blood Institute, National Institute of Mental Health o SENIOR SCIENTIST AWARD (K05) -- National Institute on Alcoholism and Alcohol Abuse, National Institute on Drug Abuse, National Institute of Mental Health o ACADEMIC CAREER AWARD (K07) -- National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute, National Institute of Environmental Health Sciences, National Institute of Mental Health o MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD (K08) -- National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute on Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute, National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute of Dental Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke o MENTORED CLINICAL SCIENTIST DEVELOPMENT PROGRAM AWARD (K12) -- National Institute on Aging, National Institute of Dental Research Applicants should direct inquiries to one of the Institute or Center contacts listed in the program announcement for each specific career award. If you need additional information about the policies and procedures related to career awards or you need assistance in identifying an appropriate contact, you may wish to write or call: Dr. Walter Schaffer Research Training and Special Program Office National Institutes of Health Building 31, Room 5B44 Bethesda, MD 20892 Telephone: (301) 496-9743 FAX: (301) 496-0166 Email: ws11q@nih.gov $$N1 END ************************************************************ $$N2 BEGIN ********************************************************** FY 95 FUNDING MECHANISMS FOR THE NATIONAL ACTION PLAN ON BREAST CANCER NIH GUIDE, Volume 24, Number 15, April 28, 1995 P.T. 34; K.W. 1014006, 0715036 National Cancer Institute PROGRAM GOALS AND SCOPE The National Action Plan on Breast Cancer (NAPBC) is a major public/private partnership created to eradicate the epidemic of breast cancer. The implementation of the Plan is coordinated by the Public Health Service's (PHS) Office on Women's Health. Several mechanisms (listed below) have been established for funding of projects that directly address the six high priority areas identified by the Plan. The six priority areas include: information dissemination, national biological resource banks, consumer involvement, breast cancer etiology, clinical trials accessibility, and issues related to breast cancer susceptibility genes. A description of the priority areas for the Innovative Small Grants and Omnibus PHS Administrative Supplements appears in the NIH Guide to Grants and Contracts noted below. INNOVATIVE SMALL GRANTS The NAPBC announced on April 7, 1995 (NIH Guide for Grants and Contracts, Volume 24, Number 13), an innovative small grants (R03) solicitation that will be administered by the PHS Office on Women's Health and funded through the National Cancer Institute (NCI). This initiative will fund grants up to $50,000 a year direct costs for up to two years. The goal of this initiative is to provide support for novel, creative pilot research and outreach projects that, if successful, will yield exceptionally important new information on breast cancer. A second goal is to support developmental, exploratory, or pilot projects that could serve as the basis for well-defined future research and outreach project applications in the area of breast cancer. The applications will be evaluated for scientific and technical merit by National Institutes of Health peer review group(s). The applications will be evaluated for relevance to the priority areas identified by Working Groups of the Plan. Applications must be submitted to the Division of Research Grants, NIH, by June 14, 1995. ADMINISTRATIVE SUPPLEMENTS TO EXISTING FEDERAL GRANTS o Public Health Service Grants -- The NAPBC announced on April 14, 1995 (NIH Guide for Grants and Contracts, Volume 24, Number 14), an Omnibus PHS Administrative Supplements solicitation for administrative supplements to existing PHS grants for up to $100,000 for one year. This omnibus administrative supplement program will be administered by the PHS Office on Women's Health and funded through the NCI. Any currently funded PHS grant relevant to breast cancer that addresses one or more of the six priority areas is eligible for an administrative supplement under this announcement. It is especially important to note that all requests for supplements MUST be within the scope of the parent grant. The parent grant can deal with breast cancer, other cancers, other diseases, or any of the above six priority areas. The program director for each grant must be contacted for questions about the consistency of the proposed supplemental project's aims with the parent project. Further, the parent grant must have a minimum of one year remaining (end date no sooner than September 30, 1996) in the project from the time the supplement is awarded. A copy of the official initial peer review comments for the grant (e.g., summary statement or the equivalent) must be submitted. For grants sponsored by agencies outside of the National Institutes of Health, the funds will be transferred to those agencies via interagency agreements. The receiving agency must obligate funds before the end of the fiscal year in accordance with that agency's operating policies and procedures. Contracts are not eligible for this supplement program. The supplements will be subject to restrictions outlined in the solicitation. Applications must be submitted to the PHS Office on Women's Health by June 14, 1995. o Grants from Other Federal Agencies -- The NAPBC also solicits with this notice requests for administrative supplements for up to $100,000 for one year to existing grants from Federal agencies outside the PHS. This administrative supplement program will be administered by the PHS Office on Women's Health and funded through the NCI. Any currently funded Federal grant relevant to breast cancer that addresses one or more of the six priority areas is eligible for an administrative supplement under this announcement. It is especially important to note that all requests for supplements MUST be within the scope of the parent grant. The parent grant can deal with breast cancer, other cancers, other diseases, or any of the above six priority areas. The program director for each grant must be contacted for questions on the consistency of the proposed supplemental project's aims with the parent project. Further, the parent grant must have a minimum of one year remaining (end date no sooner than September 30, 1996) in the project from the time the supplement is awarded. A copy of the official initial peer review comments for the grant (e.g., summary statement or the equivalent) must be submitted. The funds will be transferred to those agencies via interagency agreements. The receiving agency must obligate funds before the end of the fiscal year in accordance with the agency's operating policies and procedures. Contracts are not eligible for this supplement program. Instructions for applicants can be obtained >From the PHS Office on Women's Health. Applications must be submitted to the PHS Office on Women's Health by June 14, 1995. INTRAMURAL FEDERAL PROJECTS o Public Health Service Projects -- The NAPBC solicits with this notice requests for administrative supplements to existing intramural Federal projects and contracts supported by PHS-based agencies. This mechanism will fund supplements for up to $100,000 a year total costs for one year to PHS projects. This administrative supplement program will be administered by the PHS Office on Women's Health and funded through the NCI. Any existing PHS intramural project or contract that has relevance to breast cancer that addresses one or more of the six priority areas is eligible for an administrative supplement under this announcement. It is especially important to note that all requests for supplements MUST be within the scope of the parent project. The parent project can deal with breast cancer, other cancers, other diseases, or any of the above six priority areas. For projects in agencies outside of the National Institutes of Health, the funds will be transferred to those agencies via interagency agreements. The receiving agency must obligate funds before the end of the fiscal year in accordance with the agency's operating policies and procedures. Instructions for applicants can be obtained from the PHS Office on Women's Health. Applications must be submitted to PHS Office on Women's Health by June 14, 1995. o Projects in Other Federal Agencies -- The NAPBC solicits with this notice requests for administrative supplements to existing intramural Federal projects and contracts supported by Federal agencies outside of the PHS. This mechanism will fund supplements for up to $100,000 a year total costs for one year. This administrative supplement program will be administered by the PHS Office on Women's Health and funded through the NCI. Any existing PHS intramural project or contract that has relevance to breast cancer that addresses one or more of the six priority areas is eligible for an administrative supplement under this announcement. It is especially important to note that all requests for supplements MUST be within the scope of the parent project. The parent project can deal with breast cancer, other cancers, other diseases, or any of the above six priority areas. For projects in agencies outside of the National Institutes of Health, the funds will be transferred to those agencies via interagency agreements. The receiving agency must obligate funds before the end of the fiscal year in accordance with the agency's operating policies and procedures. Instructions for applicants can be obtained from the PHS Office on Women's Health. Applications must be submitted to PHS Office on Women's Health by June 14, 1995. SUPPORT OF PEER-REVIEWED, UNFUNDED GRANT APPLICATIONS o Public Health Service Grants -- The NAPBC solicits with this notice requests for the funding of grant applications addressing the six priority areas that have been peer-reviewed and recommended for funding between September 30, 1994, and September 30, 1995, but not awarded due to lack of sufficient funds. The initial awarding of funds cannot exceed one year. Additional funding for up to two years may be considered. Applications eligible for this mechanism should be brought to the attention of the Plan. Principal investigators who believe that their unfunded grant applications are eligible for this program should contact the PHS Office on Women's Health and their PHS program administrator. A copy of the original grant application and a copy of the official initial peer review comments for the application (e.g., summary statement or the equivalent) must be submitted to the Plan. Program administrators who identify eligible grant applications must obtain written permission from the principal investigator to submit official initial peer review comments for the application (e.g., summary statement or the equivalent) and a copy of the original grant application for funding consideration to the Plan. For selected grant applications submitted to PHS agencies outside of the National Institutes of Health, the funds will be transferred to those agencies via interagency agreements. Funds must be obligated before the end of the fiscal year. The application with a copy of the original grant application and the summary statement of review must be submitted to the PHS Office on Women's Health by June 14, 1995. o Grant Applications Submitted to Other Federal Agencies -- The NAPBC solicits with this notice requests for the funding of grant applications addressing the six priority areas that have been peer reviewed and recommended for funding between September 30, 1994, and September 30, 1995, but not awarded due to lack of sufficient funds. The initial awarding of funds cannot exceed one year. Additional funding for up to two years may be considered. Grant applications eligible for this mechanism should be brought to the attention of the Plan. Principal investigators who believe that their unfunded grant applications are eligible for this program should contact the PHS Office on Women's Health and their program administrator. A copy of the original grant application and a copy of the official initial peer review comments for the grant (e.g., summary statement or the equivalent) must be submitted to the Plan. Program administrators who identify eligible grant applications must obtain written permission from the principal investigator to submit official initial peer review comments for the grant (e.g., summary statement or the equivalent) and a copy of the original grant application for funding consideration to the Plan. If selected for support, the funds will be transferred to those agencies via interagency agreements. Funds must be obligated before the end of the fiscal year. The application with a copy of the original grant application and the summary statement of review must be submitted to the PHS Office on Women's Health by June 14, 1995. INQUIRIES For more information on the National Action Plan on Breast Cancer FY95 funding programs, contact: Susan J. Blumenthal, M.D., M.P.A. Deputy Assistant Secretary for Health (Women's Health) Co-Chair, The National Action Plan on Breast Cancer ATTN: Suzanne G. Haynes, Ph.D. (etiology; consumer involvement) Cheryl Marks, Ph.D. (clinical trials; information dissemination) Debbie Saslow, Ph.D. (breast cancer susceptibility genes; tissue banks) Diane K. Wagener, Ph.D. (general information) PHS Office on Women's Health Hubert Humphrey Building, Room 730-B 200 Independence Avenue, S.W. Washington, DC 20201 Telephone: (202) 401-9587 or (202) 690-7650 FAX: (202) 401-9590 $$N2 END ************************************************************ $$N3 BEGIN ********************************************************** COMMONLY ASKED QUESTIONS ABOUT EQUIPMENT UNDER GRANTS NIH GUIDE, Volume 24, Number 15, April 28, 1995 P.T. 34; K.W. 1014006, 0735000 National Institutes of Health The National Institutes of Health (NIH) Grants Policy Office and awarding institutes and centers frequently receive questions from research administrators and investigators regarding equipment purchased with Public Health Service (PHS) research grant funds. To assist recipients of PHS research grants, NIH staff have developed the following questions and answers regarding equipment. The information below does not represent new policy or a revision to policy. Rather, it is a summary of current regulations and policies pertaining to grant equipment. The answers provided are based on the assumption that there are no special requirements in the program legislation or regulations or special terms and conditions of award that would supersede the regulations and policies cited below. Appropriate citations to policy or regulation appear within or following each answer. The HHS regulations on the Administration of Grants appear in the Code of Federal Regulations (CFR) at 45 CFR 74 and 45 CFR 92. Part 74 is applicable to all recipients except those covered by Part 92, which governs awards to state and local governments. The regulations at Part 74 were recently revised to implement the revision to OMB Circular A-110, and were published in the Federal Register on August 25, 1994 (Vol. 59, No. 164). The PHS Grants Policy Statement (GPS) was revised effective April 1, 1994, and an addendum was effective February 15, 1995. A single copy of each was mailed to all current PHS grantee organizations, which may photocopy the documents as needed. NIH grantees that did not receive a copy may contact the NIH Division of Research Grants, Office of Grants Information, on 301/594-7248 to request a single copy. In addition, the GPS is available on the NIH Gopher. The NIH Gopher contains information about NIH, including the NIH Guide for Grants and Contracts, and has text-searching capabilities. It is possible to ~tunnel~ to the NIH Gopher (gopher.nih.gov) if you have access to a system with Gopher. Local computer support should be consulted for additional information or assistance If you have additional questions that cannot be answered by the sponsored research office at your organization, you should contact the grants management specialist identified on your PHS Notice of Grant Award. WHAT IS THE DEFINITION OF EQUIPMENT? The definition for equipment, as stated in 45 CFR Parts 74 and 92, is an article of tangible nonexpendable personal property having a useful life of more than one year and an acquisition cost of $5,000 or more per unit. However, consistent with recipient organizational policy, lower limits may be established. Grantees may implement the new definition (provided they do so consistently on an organization-wide basis) even though the definition in the cost principles may not yet correspond. (45 CFR Part 74.2 and 74.34) DOES THE $5,000 THRESHOLD (UNDER THE REVISED 45 CFR PART 74) ONLY APPLY TO EQUIPMENT PURCHASED AFTER THE EFFECTIVE DATE OF THE REVISION? No. If grantees elect to implement the revised definition, it should be applied to all grantee equipment. Grantees are not required to track equipment under two different definitions. DOES EQUIPMENT PURCHASED UNDER A GRANT BELONG TO THE PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR? PHS research grants are made to an organization on behalf of the Principal Investigator (PI) or Program Director. Title to equipment acquired with HHS funds vests in the organization receiving financial assistance directly from an HHS awarding agency to carry out a project or program, subject to certain restrictions described at 45 CFR Part 74.34 (see next question). Whereas in the past, title to equipment, property, and supplies purchased under a research grant to a for-profit organization vested in the Federal Government, the revised HHS regulations now permit for-profit grantees to retain title. (45 CFR Part 74.34) CAN HHS REQUIRE THE TRANSFER OF EQUIPMENT FROM THE GRANTEE TO ANOTHER PARTY? Yes, HHS has the right to require equipment (including title) purchased with grant funds to be transferred to the Federal Government or to an eligible third party named by the HHS awarding office, under the conditions specified in 45 CFR Part 74.34(h). Although it is seldom necessary to do so, this right may be invoked in cases wher